Shares of Emergent Biosolutions, Inc. (NYSE:EBS) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $37.60 and last traded at $37.58, with a volume of 310,669 shares changing hands. The stock had previously closed at $36.47.

Several research firms have recently commented on EBS. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Zacks Investment Research cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Emergent Biosolutions presently has an average rating of “Buy” and an average target price of $44.00.

The stock has a market capitalization of $1.55 billion, a P/E ratio of 23.97 and a beta of 1.23. The stock’s 50 day moving average price is $35.89 and its 200-day moving average price is $32.31.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The firm had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. During the same period last year, the business earned ($0.05) EPS. The business’s revenue was up 10.4% on a year-over-year basis. On average, equities analysts predict that Emergent Biosolutions, Inc. will post $1.54 EPS for the current fiscal year.

In other news, CEO Daniel Abdun-Nabi sold 15,000 shares of Emergent Biosolutions stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $37.21, for a total value of $558,150.00. Following the completion of the transaction, the chief executive officer now owns 219,134 shares of the company’s stock, valued at approximately $8,153,976.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $37.50, for a total transaction of $616,462.50. Following the completion of the transaction, the chairman now directly owns 1,605,216 shares of the company’s stock, valued at approximately $60,195,600. The disclosure for this sale can be found here. In the last three months, insiders sold 100,776 shares of company stock valued at $3,681,754. Insiders own 16.50% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Riverhead Capital Management LLC grew its position in shares of Emergent Biosolutions by 102.8% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,542 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Emergent Biosolutions by 23.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 587 shares during the period. State of Alaska Department of Revenue grew its position in shares of Emergent Biosolutions by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 100 shares during the period. Creative Planning grew its position in shares of Emergent Biosolutions by 1.2% in the 2nd quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 55 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in shares of Emergent Biosolutions by 17.3% in the 1st quarter. Envestnet Asset Management Inc. now owns 5,710 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 844 shares during the period. 85.44% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/09/emergent-biosolutions-inc-ebs-hits-new-52-week-high-at-37-60.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).